Karyopharm Therapeutics Affirms FY2026 Sales Guidance of $130.000M-$150.000M vs $137.489M Est

Benzinga Newsdesk www.benzinga.com Negative 60.3%

Neg 60.3% Neu 0% Pos 0%

Karyopharm Therapeutics (NASDAQ:KPTI) affirms FY2026 sales outlook from $130.000 million-$150.000 million to $130.000 million-$150.000 million vs $137.489 million estimate.